EEDQ

peptide coupling reagent

Also Known As:

2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline; BC 681; N-carbethoxy-2-ethoxy-1,2-dihydroquinoline; N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; 2-ethoxy-1(2H)-quinolinecarboxylic acid, ethyl ester

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - EEDQ: 5

Related Diseases

1.	Shock 06/01/1999 - "N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline studies on the role of 5-HT1A and 5-HT2 receptors in mediating foot-shock-induced ultrasonic vocalisation in adult rats." 06/01/1999 - "Pretreatment with EEDQ (24 h, subcutaneous [s.c.]) inhibited foot-shock-induced ultrasonic vocalisation (effective dose50=0.95 micromol/kg) and decreased [3H]-8-OH-DPAT and [3H]-ketanserin binding in the brain. "
2.	Catalepsy 08/25/1987 - "EEDQ administration also induces catalepsy behavior and impairs ability of animals to remain on an inclined screen. " 07/01/1994 - "The results in the EEDQ test were related to the potency to block d-amphetamine-induced hyperlocomotion and the ability to induce bar-test catalepsy in the rat. "
3.	Hypothermia 07/01/1994 - "4. Pretreatment with the selective alpha 2-adrenoceptor antagonist, RX 821002 (0.1-3.0 mg kg-1, i.p.) 45 min before EEDQ prevented the loss of alpha 2-adrenoceptors as well as the blockade of medetomide-induced sedation and hypothermia by EEDQ. "
4.	Glioma (Gliomas) 08/01/1986 - "Treatment of intact L6 myoblasts or C6 glioma cells with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) inactivated beta-adrenergic receptors on membranes prepared from these cells. "

Related Drugs and Biologics

1.	EEDQ
2.	beta Adrenergic Receptors
3.	Ketanserin
4.	Dextroamphetamine (Dexedrine)
5.	2-methoxyidazoxan
6.	hydroxide ion